Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684795 | 0.87 | PNMT (0.39) | PNMTHTR6PARP1 | |
| SCHEMBL19684796 | 0.84 | PNMT (0.49) | PNMTHTR6 | |
| SCHEMBL17462475 | 0.84 | PNMT (0.37) | PNMTHTR6PARP1 | |
| SCHEMBL23735162 | 0.84 | PNMT (0.37) | PNMTHTR6PARP1 | |
| SCHEMBL19684792 | 0.84 | PNMT (0.37) | PNMTHTR6PARP1 | |
| SCHEMBL19684791 | 0.82 | PNMT (0.36) | PNMTHTR6PARP1 | |
| SCHEMBL19684830 | 0.81 | PNMT (0.37) | PNMTHTR6 | |
| SCHEMBL19678859 | 0.81 | HTR2A (0.35) | PNMTHTR6PARP1 | |
| SCHEMBL20778128 | 0.81 | PNMT (0.35) | PNMTHTR6PARP1 | |
| SCHEMBL19684833 | 0.81 | HTR2A (0.35) | PNMTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2017213825-A1 | TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS | TABULA RASA HEALTHCARE, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885HTR6 4627/4885PARP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.